Report Highlights

Osteoarthritis in the United States: Market Overview

The United States osteoarthritis market was valued at USD 7.4 billion in 2024, spanning prescription analgesics, intra-articular injectables, topical agents, and knee and hip replacement pathways. The Centers for Disease Control and Prevention estimates that about 32.5 million American adults have doctor-diagnosed osteoarthritis, sustaining high patient volumes across primary care and orthopedic practice. Private firms including Pacira BioSciences, Anika Therapeutics, and Stryker drive innovation in extended-release injectables, viscosupplements, and robotic surgery.

Government has been the dominant force in pricing and access. The Centers for Medicare and Medicaid Services sets reimbursement through Medicare Part B and Part D, shaping which molecules and procedures reach volume, and Medicare coverage determinations effectively price the category for commercial payers that follow them. The National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, funds foundational research that later de-risks private trials, while manufacturers carry launch capital and commercial execution.

Policy-Driven Growth in U.S. Osteoarthritis Care

The Inflation Reduction Act of 2022 (Public Law 117-169) is the most consequential demand-side policy for oral osteoarthritis therapy. Part D out-of-pocket spending is capped at USD 2,000 for 2025, and the statute authorizes Medicare to negotiate maximum fair prices, with the first ten negotiated prices effective 1 January 2026. The cap removes a patient-level barrier to branded oral analgesics, so older adults with multiple joint complaints refill more consistently, expanding Part D volumes for established agents.

The Centers for Medicare and Medicaid Services added total knee arthroplasty to the Medicare Ambulatory Surgical Center covered procedures list in the CY2018 final rule, and removed it from the Medicare inpatient-only list in the same rulemaking cycle. That shift moved a large share of knee replacement from hospitals to ambulatory surgery centers, creating recurring demand for pre-operative injectables and outpatient pain protocols. The Comprehensive Care for Joint Replacement model, launched in 2016, reinforces the trend by paying hospitals bundled episode prices, which rewards faster-recovery pathways built on corticosteroid and analgesic regimens.

Regulatory Barriers and Compliance Costs

Hyaluronic acid viscosupplements require premarket approval from the FDA's Center for Devices and Radiological Health under the Medical Device Amendments of 1976, classified as Class III devices. Original PMA user fees alone run into the hundreds of thousands of dollars, and pivotal trials commonly span multiple years. Prescription NSAIDs carry a separate burden: the FDA's Center for Drug Evaluation and Research strengthened cardiovascular and gastrointestinal warnings in 2015, forcing label revisions that generic and brand manufacturers must implement.

Medicare coverage presents the most restrictive barrier. Contractors administering Medicare under Title XVIII of the Social Security Act have repeatedly declined to cover viscosupplement injections for knee osteoarthritis, leaving most patients to pay out of pocket. Opioid therapy faces the strictest rules: the Drug Enforcement Administration controls prescribing under the Controlled Substances Act, while the CDC's 2022 Clinical Practice Guideline for Prescribing Opioids for Pain and state prescription drug monitoring programs add documentation and checking steps that lengthen each prescribing encounter.

Policy-Created Opportunities in the United States

The 21st Century Cures Act of 2016 created Regenerative Medicine Advanced Therapy designation at the FDA, which offers intensive sponsor guidance and rolling review to cell-based and tissue therapies for cartilage repair. Developers pursuing disease-modifying cartilage products can secure this designation before full Phase 3 data are available. Commercial partners that license RMAT-designated candidates early can capture the first disease-modifying option the U.S. market has lacked.

Ambulatory surgery centers represent the clearest opportunity. Because CMS moved knee arthroplasty into the ambulatory setting, outpatient facilities need reimbursement-compliant pre-operative and post-operative injectable protocols. Device and drug companies that supply bundled kits, prior authorization support, and CMS-compliant documentation for ASC use will capture share from hospital outpatient departments with less flexibility in contract pricing.

Market at a Glance

Leading Market Participants

• Pacira BioSciences
• Anika Therapeutics
• Sanofi
• Pfizer
• Stryker
• Zimmer Biomet
• Smith+Nephew
• Johnson & Johnson
• Haleon
• Bioventus

Regulatory and Policy Environment

The primary legislation governing U.S. osteoarthritis products is the Federal Food, Drug, and Cosmetic Act, administered by the FDA, supplemented by the Medical Device Amendments of 1976 for viscosupplements and the Controlled Substances Act for opioids. Reimbursement is governed by Title XVIII of the Social Security Act and the Inflation Reduction Act of 2022. Key compliance requirements include PMA approval with post-approval study commitments, quality system requirements under 21 CFR Part 820 moving to an ISO 13485-aligned framework in February 2026, Medicare contractor coverage evidence, and DEA registration for prescribers.

Upcoming changes include the second IRA negotiation cycle, covering 15 Medicare drugs for 2027 with Part B drugs added from 2028, and reauthorization of the Medical Device User Fee Amendments, which expire in September 2027. Against regional peers, the U.S. device route is faster than the EU Medical Device Regulation (EU) 2017/745 with its notified-body certification, yet it lacks the centralized price and clinical-value gates of Canada's pCPA negotiations and England's NICE, whose guideline NG226 advises against routine hyaluronic acid injections.

Long-Term Policy Outlook for U.S. Osteoarthritis Care

By 2032, Medicare negotiation will extend to Part B drugs from 2028, pressuring physician-administered injectables and creating pricing benchmarks that reach extended-release corticosteroids such as Pacira's Zilretta. The Ambulatory Specialty Model, finalized in CMS's CY2026 Physician Fee Schedule and starting January 2027, will push elective joint procedures further toward ambulatory settings, where pre-operative pain management drives product selection.

The reauthorization of the Medical Device User Fee Amendments in 2027 will shape viscosupplement evidence requirements, and FDA scrutiny of NSAID cardiovascular risk will continue. Policy-driven substitution toward non-opioid analgesics and toward devices backed by Medicare coverage evidence will reshape the market, with growth concentrated in products that secure durable reimbursement rather than those relying on cash-pay demand.